98%
921
2 minutes
20
Autosomal recessive renal tubular dysgenesis (RTD) is a rare genetic disorder caused by defects in the renin-angiotensin system, with the most common outcomes being foetal or neonatal death from renal failure, pulmonary hypoplasia and/or refractory arterial hypotension. A small proportion of patients survive past the neonatal period. We present the case of a toddler with RTD due to compound heterozygous variants in the gene that codes for ACE, who has not required renal replacement therapy to date and in whom fludrocortisone has achieved electrolyte and acid/base balance.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1136/bcr-2025-266131 | DOI Listing |
Physiol Rep
September 2025
Department of Medicine, Dunedin School of Medicine, University of Otago, Dunedin, New Zealand.
Lithium-induced kidney injury is commonly associated with the development of nephrogenic diabetes insipidus. Longer term lithium exposure is associated with the development of chronic interstitial fibrosis. The mechanisms of lithium-induced kidney injury are multifaceted, affecting many intracellular cell signaling pathways associated with cell cycle regulation, cell proliferation, and subsequent increased extracellular matrix formation and interstitial fibrosis.
View Article and Find Full Text PDFBMJ Case Rep
September 2025
Guy's and St Thomas' Hospitals NHS Trust, London, England, UK.
Autosomal recessive renal tubular dysgenesis (RTD) is a rare genetic disorder caused by defects in the renin-angiotensin system, with the most common outcomes being foetal or neonatal death from renal failure, pulmonary hypoplasia and/or refractory arterial hypotension. A small proportion of patients survive past the neonatal period. We present the case of a toddler with RTD due to compound heterozygous variants in the gene that codes for ACE, who has not required renal replacement therapy to date and in whom fludrocortisone has achieved electrolyte and acid/base balance.
View Article and Find Full Text PDFMethods Cell Biol
September 2025
Renal Physiopathology Laboratory, Department of Nephrology, Instituto de Investigación Sanitaria Gregorio Marañón, Hospital General Universitario Gregorio Marañón, Madrid, Spain; Department of Physiology, School of Medicine, Universidad Complutense de Madrid, Madrid, Spain. Electronic address:
Chronic kidney disease (CKD) is currently a serious global health problem, due to its high risk of progression, prevalence and mortality. It not only affects the kidneys but also causes multi-organ damage. Moreover, there is no effective pharmacological treatment, and the only available alternatives are dialysis or transplantation, both of which impose a significant financial burden on healthcare systems.
View Article and Find Full Text PDFBiomed Mater
September 2025
Extracorporeal Therapy Systems (EXTHER), Fraunhofer Institute for Cell Therapy and Immunology IZI, Schillingallee 68, 18057 Rostock, Rostock, 18057, GERMANY.
The global rise in chronic kidney disease necessitates innovative solutions for end-stage renal dis-ease that can help to overcome the limitations of the only available treatment options, transplanta-tion and dialysis. Tissue engineering presents a promising alternative, leveraging decellularized scaffolds to retain the extracellular matrix (ECM). However, optimizing methods for decellularization and recellularization remains a challenge.
View Article and Find Full Text PDFPhytomedicine
September 2025
School of Pharmaceutical Sciences, Zhejiang Chinese Medical University, Hangzhou 310000, China; Academy of Chinese Medical Sciences, Zhejiang Chinese Medical University, Hangzhou 310053, China. Electronic address:
Background: Renal fibrosis is a common terminal pathway for various CKDs. Shenqi Wan (SQW) can reduce the development of renal fibrosis and may be associated with aquaporin 1 (AQP1) as discovered previously.
Purpose: The mechanism of SQW in mitigating the progression of renal fibrosis and alleviating CKD was analyzed.